On October 30, the DEA announced that Insys Therapy applied to produce marijuana and THC for circulation. In 2016, Insys Therapeutics donated $500,000 to help defeat Prop 205, a recreational cannabis initiative in Arizona, Filter reports. Then, in 2017, Insys received FDA approval to distribute Syndros, their artificial form of THC.
The DEA published online that:” The company prepares to make bulk artificial active pharmaceutical active ingredients (APIs) for item development and circulation to its consumers. No other activity for these drug codes are authorized for this registration.”
The DEA’s online document has a comment period that ends on Dec 31, 2018.
Photo: Glassdoor (goo.gl/ ybKPnN)